Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Infinity Pharmaceuti (INFI)

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,267
  • Shares Outstanding, K 89,155
  • Annual Sales, $ 1,860 K
  • Annual Income, $ -45,260 K
  • 60-Month Beta 2.16
  • Price/Sales 30.07
  • Price/Cash Flow N/A
  • Price/Book 5.70
Trade INFI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.52
  • Most Recent Earnings -0.14 on 05/03/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 192.54% ( -111.49%)
  • Historical Volatility 127.35%
  • IV Percentile 96%
  • IV Rank 50.51%
  • IV High 334.89% on 05/04/22
  • IV Low 47.26% on 02/15/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 7,589
  • Open Int (30-Day) 7,780

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.13
  • Low Estimate -0.15
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4605 +34.61%
on 05/12/22
0.8850 -29.95%
on 04/26/22
-0.2315 (-27.19%)
since 04/22/22
3-Month
0.4605 +34.61%
on 05/12/22
1.2900 -51.95%
on 03/30/22
-0.4001 (-39.23%)
since 02/23/22
52-Week
0.4605 +34.61%
on 05/12/22
3.8900 -84.06%
on 09/02/21
-2.5101 (-80.19%)
since 05/21/21

Most Recent Stories

More News
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced...

INFI : 0.6199 (-1.07%)
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

INFI : 0.6199 (-1.07%)
CORT : 20.05 (-1.81%)
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming...

INFI : 0.6199 (-1.07%)
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference...

INFI : 0.6199 (-1.07%)
JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?

Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.

JAZZ : 145.50 (-2.04%)
INFI : 0.6199 (-1.07%)
AXSM : 28.16 (-11.03%)
HOWL : 4.18 (-7.11%)
Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, granted...

INFI : 0.6199 (-1.07%)
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 10.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

INFI : 0.6199 (-1.07%)
ADMP : 0.4069 (-1.52%)
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming...

INFI : 0.6199 (-1.07%)
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference...

INFI : 0.6199 (-1.07%)
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates

Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 4.94% and 42.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?...

MRNS : 5.47 (+2.82%)
INFI : 0.6199 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

3rd Resistance Point 0.6790
2nd Resistance Point 0.6604
1st Resistance Point 0.6401
Last Price 0.6199
1st Support Level 0.6012
2nd Support Level 0.5826
3rd Support Level 0.5623

See More

52-Week High 3.8900
Fibonacci 61.8% 2.5799
Fibonacci 50% 2.1753
Fibonacci 38.2% 1.7706
Last Price 0.6199
52-Week Low 0.4605

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar